XML 103 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet.  The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):
Fair value of consideration received
$
13,397.9

Carrying value of segment non-controlling interest
6,015.0

Carrying value of segment accumulated comprehensive income
4,387.4

 
$
23,800.3

Less carrying amount of assets and liabilities sold:
 
Cash
$
8,457.5

Restricted Cash
2,918.1

Accounts Receivable
6,130.2

Inventories
15,077.7

Prepaid expenses and other current assets
957.8

Property, plant and equipment, net
38,102.0

Other assets
5,946.3

Accounts payable
(9,604.8
)
Accrued liabilities
(2,008.8
)
Bank loans
(15,133.5
)
Notes payable
(6,599.3
)
Other liabilities
(9,166.8
)
Amount due related party
(7,859.7
)
 
$
27,216.7

 
 
Loss on exit of segment
$
(3,416.4
)
Balance Sheet [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):
 
December 31, 2011
Assets:
 

Cash and cash equivalents
$
103.3

Prepaid expenses and other current assets
284.4

Property, plant and equipment, net
1,256.8

Other Assets
149.0

 
$
1,793.5

Liabilities:
 
Accounts payable
$
177.8

Accrued liabilities
31.0

 
$
208.8
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Pharmaceutical Manufacturing - China discontinued operations as of December 31, 2011 were as follows (in thousands):
 
December 31, 2011
Cash and cash equivalents
$
8,707.0

Accounts receivable, net
5,525.7

Inventory
16,505.7

Deferred income taxes
463.7

Prepaid expenses and other current assets
777.5

Property, plant and equipment, net
36,490.4

Land use rights, net
4,872.4

Goodwill
8,495.7

Intangible assets, net
21,846.4

Other assets
2,459.9

Total assets
$
106,144.4

 
 
Accounts payable
$
7,950.3

Accrued liabilities
1,705.8

Bank loans
15,712.0

Income tax payable
621.6

Deferred income taxes
6,177.4

Unearned revenue
1,315.4

Amount due related parties
20,862.7

Total liabilities
$
54,345.2
Income Statement [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Regenerative Medicine – China business for the years ended December 31, 2012 and 2011, which are included in discontinued operations, were as follows (in thousands):
 
Year Ended December 31,
 
2012
 
2011
Revenue
$
52.3

 
$
274.3

Cost of revenues
(30.6
)
 
(140.6
)
Research and development
(103.3
)
 
(378.3
)
Selling, general, and administrative
(497.3
)
 
(3,089.8
)
Other income (expense)
(6.8
)
 
(9.7
)
Loss on exit of segment
(1,138.0
)
 
—

Loss from discontinued operations
$
(1,723.7
)
 
$
(3,344.1
)
As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
Cash
$
195.1

Prepaid expenses and other current assets
14.9

Property, plant and equipment, net
1,023.7

Other Assets
330.5

Accounts payable
(177.1
)
Accrued liabilities
(79.2
)
Accumulated comprehensive income
(169.9
)
Loss on exit of segment
$
1,138.0
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Pharmaceutical Manufacturing - China business for the years ended December 31, 2012 and 2011 were as follows (in thousands):
 
Year Ended December 31,
 
2012
 
2011
Revenue
$
61,703.1

 
$
63,393.6

Cost of revenues
(40,245.2
)
 
(47,186.8
)
Research and development
(1,836.4
)
 
(2,904.1
)
Selling, general, and administrative
(10,740.0
)
 
(11,068.2
)
Other expense
(1,045.2
)
 
(1,081.4
)
Provision for income taxes
(1,794.1
)
 
(392.8
)
Asset impairments
(31,170.1
)
 
(19,432.7
)
Loss on sale of segment
(3,416.4
)
 
—

Loss from discontinued operations
$
(28,544.3
)
 
$
(18,672.4
)